Press Release

Printer Friendly Version View printer-friendly version
<< Back
BeyondSpring Chief Medical Officer Presents at Three Prominent Industry Conferences in March 2018
Dr. Ramon Mohanlal’s Discussions Take Place at BIO-Europe Spring, Immuno-Oncology Strategy Meeting and BIO-Asia International Conference

NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical-stage biopharmaceutical company focused on the development of transforming immuno-oncology cancer therapies, today announced that Dr. Ramon Mohanlal, the Company’s Chief Medical Officer, presents at three leading industry conferences this month:

  • BIO-Europe Spring, March 13, 2018, 3:15 p.m. CET / 10:15 a.m. EST: Dr. Mohanlal’s presentation provided a corporate update on the development of BeyondSpring’s innovative pipeline. The presentation took place at the Amsterdam RAI Convention Center in the Netherlands.
  • Immuno-Oncology Strategy Meeting, March 14, 2018, 4:20 p.m. EST: Dr. Mohanlal’s presentation focused on triple combination approaches to prevent immune-related adverse events, as well as how to better manage IR-AEs through oral immuno-oncology agents with shorter half-lives. Dr. Mohanlal was joined by several leaders in the immuno-oncology field as fellow panelists. The presentation took place at the Doubletree by Hilton in Philadelphia, Pa.
  • BIO-Asia International Conference, March 19, 2018, 9 p.m. EST / March 20, 2018, at 10:30 a.m. JST: Dr. Mohanlal will also present the Company’s innovative pipeline in the second floor Drawing Room at the Grand Hyatt Tokyo in Japan.

BIO-Europe Spring took place from March 12 through 14; the Immuno-Oncology Strategy Meeting took place on March 14 and BIO-Asia International will take place from March 19 through 20, 2018.

About BeyondSpring
BeyondSpring is a global clinical stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with University of Washington in de novo drug discovery using ubiquitination platform. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer (Study 103) and two Phase 2/3 clinical programs in the prevention of chemotherapy-induced neutropenia (CIN) – (Studies 105 and 106). BeyondSpring has a seasoned management team with many years of experience bringing drugs to market.

About Plinabulin
Studies on Plinabulin's mechanism of action indicate that Plinabulin activates GEF-H1, a guanine nucleotide exchange factor. GEF-H1 activates downstream transduction pathways leading to the activation of the protein c-Jun. Activated c-Jun enters the nucleus of dendritic cells to up-regulate immune-related genes, which contributes to the up-regulation of a series of genes leading to dendritic cell maturation, T-cell activation and other effects that prevent neutropenia. To reduce CIN, Plinabulin is given as a single IV infusion in each cycle, 30 minutes to 1 hour after completion of the chemotherapy, offering same day dosing, whereas G-CSF is given 24 hours after chemotherapy. In addition, the use of Plinabulin is not associated with bone pain, which is a frequent side effect with G-CSF.

Cautionary Note Regarding Forward-Looking Statements
This press release includes forward-looking statements that are not historical facts. Words such as "will," "expect," "anticipate," "plan," "believe," "design," "may," "future," "estimate," "predict," "objective," "goal," or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, the anticipated amount needed to finance the company's future operations, unexpected results of clinical trials, delays or denial in regulatory approval process, our expectations regarding the potential safety, efficacy or clinical utility of our product candidates, or additional competition in the market. The forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

Media Relations:
Caitlin Kasunich / Amy Singh
KCSA Strategic Communications
212.896.1241 / 212.896.1207
ckasunich@kcsa.com / asingh@kcsa.com

BeyondSpring, Inc.
Print Page Print Page | Email Page Email Page | RSS Feeds RSS Feeds | Email Alerts Email Alerts | IR Contacts Contact IR | Financial Tear Sheet Financial Tear Sheet